- Fulgent Genetics - Leader in Next Generation Sequencing
Fulgent Oncology aims to make a difference in cancer care by using precision medicine to deliver clinically relevant results Our test menu is designed to cover each patient's journey—From diagnosis and treatment to long-term care and monitoring
- Fulgent Genetics | About Us
Fulgent Genetics was the first clinical laboratory to offer copy number variation detection using NGS technology in the United States Today, we continue to offer an unrivaled catalog of genetic testing, including over 18,000+ single gene tests, 900+ rare disease tests, whole genome sequencing, whole genome copy number variation analysis
- Beacon Carrier Screening - Fulgent Genetics
Backed by Fulgent's Clinical Expertise Our lab is CLIA certified and CAP accredited, meeting the highest standards for patient privacy and test accuracy Our Beacon tests are regularly reviewed and updated based on the latest recommendations and guidance from experts in the field
- Provider Login | Fulgent Genetics
Secure login page for healthcare providers to access Fulgent Genetics services and resources
- Whole Exome - Fulgent Genetics
Overview: Whole Exome Sequencing is a patient-centric, phenotype-driven analyses designed to examine coding regions and splice junctions for over 20,000 genes, and report only the variants which are of plausible clinical relevance for your patient
- Beacon Carrier Screening Tests - Fulgent Genetics
Fulgent is an accredited leader in clinical diagnostic genetic sequencing
- Fulgent Reports First Quarter 2025 Financial Results
EL MONTE, Calif -- (BUSINESS WIRE)--May 2, 2025-- Fulgent Genetics, Inc (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its first quarter ended March 31, 2025
- How It Works - Fulgent Genetics
Our testing process in detail, from placing an order, to collecting a specimen, to receiving results
|